Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Early Enhancement of IgM Expression and Signaling Capacity during Ibrutinib Therapy in CLL Patients

Samantha Drennan, PhD, Giorgia Chiodin, MS, Annalisa D'Avola, MSc, Peter W Johnson, MD, Livio Trentin, MD, Graham Packham, PhD, Andrew J Steele, PhD, Freda K Stevenson, DPhil, Francesco Forconi, MD DM, PhD FRCPath

Blood (2016) 128 (22): 4381.

https://doi.org/10.1182/blood.V128.22.4381.4381

Published: 2016

Journal Articles

An Adjustable Markov Model to Project Life Expectancy (LE) for Early Stage Favorable Risk Hodgkin Lymphoma Patients Treated with Contemporary Therapy

Michael J. Kelly, MD MPH, MS, Susan K Parsons, MDMRP, David C. Hodgson, MD, Joshua T Cohen, PhD, Jennifer M Yeh, MD PhD, Jeremy S. Abramson, MD, Debra L. Friedman, MD MS, Tara O Henderson, MDMPH, Peter W Johnson, MD, Stephen G Pauker, MD, John M. Raemaekers, MD PhD, Jane N. Winter, MD, Kara M. Kelly, MD, Ralph M. Meyer, MD, Sharon M Castellino, MD, Andrew M. Evens, DO, MSc

Blood (2015) 126 (23): 2635.

https://doi.org/10.1182/blood.V126.23.2635.2635

Published: 2015

Journal Articles

IL-10 Production By CLL Cells Is Enhanced in the Anergic IGHV Mutated Subset and Associates with Reduced DNA Methylation of the IL-10 Locus

Samantha Drennan, PhD, Annalisa D'Avola, MSc, Yifang Gao, PhD, Eleni Chrysostomou, MSc, Andrew J Steele, PhD, Thorsten Zenz, MD, Christoph Plass, PhD, Peter W Johnson, MD, Anthony P Williams, PhD FRCPath, Graham Packham, PhD, Freda K Stevenson, DPhil, Christopher C. Oakes, PhD, Francesco Forconi, MD DM, PhD FRCPath

Blood (2015) 126 (23): 2917.

https://doi.org/10.1182/blood.V126.23.2917.2917

Published: 2015

Journal Articles

The Syk\Jak Inhibitor Cerdulatinib (PRT062070) Shows Promising Preclinical Activity in Chronic Lymphocytic Leukemia By Antagonising B Cell Receptor and Microenvironmental Signalling

Matthew D Blunt, PhD, Jack Parnell, BSc(hons), Marta Larrayoz, PhD, Lindsay Smith, PhD, Rachel Dobson, BSc(Hons), Jonathan C Strefford, PhD, Freda K Stevenson, DPhil, Francesco Forconi, MD DM, PhD FRCPath, Andrew J Davies, MRCP, Peter W Johnson, MD, Graham Packham, PhD, Greg P. Coffey, PhD, Mark S Cragg, PhD, Andrew J Steele, PhD

Blood (2015) 126 (23): 1716.

https://doi.org/10.1182/blood.V126.23.1716.1716

Published: 2015

Journal Articles

Outcome of Elderly Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: Subgroup Analysis from the UK NCRI R-CHOP 14 Vs 21 Trial

Blood (2015) 126 (23): 1516.

https://doi.org/10.1182/blood.V126.23.1516.1516

Published: 2015

Journal Articles

Single-Agent Ibrutinib Demonstrates Safety and Durability of Response at 2 Years Follow-up in Patients with Relapsed or Refractory Mantle Cell Lymphoma: Updated Results of an International, Multicenter, Open-Label Phase 2 Study

Blood (2014) 124 (21): 4453.

https://doi.org/10.1182/blood.V124.21.4453.4453

Published: 2014

Journal Articles

A Phase II Open-Label, Multi-Center Study of Anti-CCR4 Monoclonal Antibody Mogamulizumab (KW-0761) in Patients with Previously Treated Peripheral T-Cell Lymphoma(PTCL)

Pier Luigi Zinzani, Bertrand Coiffier, MD PhD, John Radford, Dolores Caballero, Paul Fields, MD PhD, Martine ED Chamuleau, MD, Francesco d'Amore, Corinne Haioun, MD PhD, Catherine Thieblemont, MD PhD, Eva González Barca, MD PhD, Carlos Grande García, MD, Peter W Johnson, MD, Gustaaf W van Imhoff, MD PhD, Andrew Saunders, MD, Karen Dwyer, Franck Morschhauser, MD PhD

Blood (2014) 124 (21): 1763.

https://doi.org/10.1182/blood.V124.21.1763.1763

Published: 2014

Journal Articles

Surface IgM Levels Independently Influence Clinical Behavior and Associate with Altered Phenotype and Genetics in Chronic Lymphocytic Leukemia

Samantha J Drennan, PhD, Annalisa D'Avola, MSc, Ian Tracy, Isla Henderson, Marta Larrayoz, PhD, Carina Mundy, Andrew S. Duncombe, MD, Andrew J. Davies, MD PhD, Davide Rossi, MD PhD, Fiona M Ross, DPhil, Laura Chiecchio, PhD, Kathleen N. Potter, PhD, Jonathan Strefford, PhD, Andrew J Steele, PhD, Peter W Johnson, MD, Graham Packham, PhD, Freda K Stevenson, DPhil, Francesco Forconi, MD DM, PhD FRCPath

Blood (2014) 124 (21): 830.

https://doi.org/10.1182/blood.V124.21.830.830

Published: 2014

Journal Articles

The Addition of Rituximab to Fludarabine and Cyclophosphamide (FC) Improves Overall Survival in Newly Diagnosed Mantle Cell Lymphoma (MCL): Results of the Randomised UK National Cancer Research Institute (NCRI) Trial

Simon Rule, MD, Paul Smith, Peter W Johnson, MD, Simon Bolam, MD, George A Follows, Jo Gambell, Peter Hillmen, MBChB, PhD, Andrew Jack, PhD, MB, Stephen A. N. Johnson, MBBS, FRCP, FRCPath, Amy Kirkwood, Anton Kruger, MBChB, FRCP, FRCPath, John F. Seymour, MD, PhD, Milena Toncheva, Jan Walewski, MD, PhD, David C Linch, MD FMedSci

Blood (2011) 118 (21): 440.

https://doi.org/10.1182/blood.V118.21.440.440

Published: 2011

Journal Articles

First Analysis of a Phase II Study of Rituximab-Gemcitabine, Cyclophosphamide, Vincristine and Prednisolone (R-GCVP) for Diffuse Large B Cell Lymphoma (DLBCL) Patients Considered Unsuitable for Anthracycline Containing Chemo-Immunotherapy. An NCRI Lymphoma Clinical Studies Group Trial

Paul Fields, MD, PhD, Andrew Webb, MD, Christopher FE Pocock, MD, PhD, William Townsend, Paul Smith, Amy Kirkwood, Nadjet El-Mehidi, PhD, Peter W Johnson, MD, John Radford, MD, David C Linch, MD FMedSci, David Cunningham, MD

Blood (2011) 118 (21): 1634.

https://doi.org/10.1182/blood.V118.21.1634.1634

Published: 2011

Journal Articles

Non-Cognate Cytotoxic T Cells Can Be Retargeted Against CD20 Positive Tumour Cells Using [Fab' × MHC Class I/Peptide] Conjugates.

Angela D Hamblin, BA, MRCP, Ben CR King, PhD, Ruth R French, PhD, Claude H Chan, PhD, Alison L Tutt, MPhil, Philip M Savage, PhD, FRCP, Peter W Johnson, MD, FRCP, Martin J Glennie, PhD

Blood (2010) 116 (21): 2838.

https://doi.org/10.1182/blood.V116.21.2838.2838

Published: 2010

Journal Articles

Chlorambucil Plus Rituximab Produces Better Event-Free Survival in Comparison with Chlorambucil Alone in the Treatment of MALT Lymphoma: 5-Year Analysis of the 2-Arms Part of the IELSG-19 Randomized Study

Blood (2010) 116 (21): 432.

https://doi.org/10.1182/blood.V116.21.432.432

Published: 2010

Journal Articles

Defects In Lymphocyte Subsets and Serological Memory Persist a Median of 10 Years After High Dose Therapy and Autologous Progenitor Cell Rescue for Malignant Lymphoma

Harry F Dean, BSc, Angelica Cazaly, PhD, Carol Hurlock, Anthony P Williams, MRCP, FRCPath, PhD, Peter W Johnson, MD, FRCP, Andrew J Davies, MRCP, PhD

Blood (2010) 116 (21): 1265.

https://doi.org/10.1182/blood.V116.21.1265.1265

Published: 2010

Journal Articles

Cyclophosphamide Induced CD11b + Cells Can Inhibit Anti-CD40 Monoclonal Antibody (mAb) Therapy of B-Cell Lymphoma.

Jamie Honeychurch, PhD, Martin J. Glennie, PhD, Peter W. Johnson, MD, Tim M. Illidge, MD, PhD

Blood (2004) 104 (11): 3280.

https://doi.org/10.1182/blood.V104.11.3280.3280

Published: 2004

NARROW

Early Enhancement of IgM Expression and Signaling Capacity during Ibrutinib Therapy in CLL Patients

An Adjustable Markov Model to Project Life Expectancy (LE) for Early Stage Favorable Risk Hodgkin Lymphoma Patients Treated with Contemporary Therapy

IL-10 Production By CLL Cells Is Enhanced in the Anergic IGHV Mutated Subset and Associates with Reduced DNA Methylation of the IL-10 Locus

The Syk\Jak Inhibitor Cerdulatinib (PRT062070) Shows Promising Preclinical Activity in Chronic Lymphocytic Leukemia By Antagonising B Cell Receptor and Microenvironmental Signalling

Outcome of Elderly Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: Subgroup Analysis from the UK NCRI R-CHOP 14 Vs 21 Trial

Single-Agent Ibrutinib Demonstrates Safety and Durability of Response at 2 Years Follow-up in Patients with Relapsed or Refractory Mantle Cell Lymphoma: Updated Results of an International, Multicenter, Open-Label Phase 2 Study

A Phase II Open-Label, Multi-Center Study of Anti-CCR4 Monoclonal Antibody Mogamulizumab (KW-0761) in Patients with Previously Treated Peripheral T-Cell Lymphoma(PTCL)

Surface IgM Levels Independently Influence Clinical Behavior and Associate with Altered Phenotype and Genetics in Chronic Lymphocytic Leukemia

The Addition of Rituximab to Fludarabine and Cyclophosphamide (FC) Improves Overall Survival in Newly Diagnosed Mantle Cell Lymphoma (MCL): Results of the Randomised UK National Cancer Research Institute (NCRI) Trial

First Analysis of a Phase II Study of Rituximab-Gemcitabine, Cyclophosphamide, Vincristine and Prednisolone (R-GCVP) for Diffuse Large B Cell Lymphoma (DLBCL) Patients Considered Unsuitable for Anthracycline Containing Chemo-Immunotherapy. An NCRI Lymphoma Clinical Studies Group Trial

Non-Cognate Cytotoxic T Cells Can Be Retargeted Against CD20 Positive Tumour Cells Using [Fab' × MHC Class I/Peptide] Conjugates.

Chlorambucil Plus Rituximab Produces Better Event-Free Survival in Comparison with Chlorambucil Alone in the Treatment of MALT Lymphoma: 5-Year Analysis of the 2-Arms Part of the IELSG-19 Randomized Study

Defects In Lymphocyte Subsets and Serological Memory Persist a Median of 10 Years After High Dose Therapy and Autologous Progenitor Cell Rescue for Malignant Lymphoma

Cyclophosphamide Induced CD11b + Cells Can Inhibit Anti-CD40 Monoclonal Antibody (mAb) Therapy of B-Cell Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only